Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Apr 27, 2011	ARROWHEAD RESEARCH ANNOUNCES RNAI LEADER JOHN J. ROSSI, PH.D. TO JOIN CALANDO SCIENTIFIC ADVISORY BOARD ARROWHEAD RESEARCH ANNOUNCES RNAI LEADER JOHN J. ROSSI, PH.D. TO JOIN CALANDO SCIENTIFIC ADVISORY BOARD PASADENA, Calif. — April 27, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced	View HTML ARROWHEAD RESEARCH ANNOUNCES RNAI LEADER JOHN J. ROSSI, PH.D. TO JOIN CALANDO SCIENTIFIC ADVISORY BOARD 16.7 KB
Toggle Summary Apr 6, 2011	ARROWHEAD RESEARCH INCREASES OWNERSHIP IN ABLARIS TO 64% Ablaris Secures $2.9 Million to Enter Phase I Trial in Second Half 2011	View HTML ARROWHEAD RESEARCH INCREASES OWNERSHIP IN ABLARIS TO 64% 16 KB
Toggle Summary Mar 8, 2011	Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16 Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16 PASADENA, Calif. — March 8, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today	View HTML Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16 12.5 KB
Toggle Summary Feb 10, 2011	ARROWHEAD REPORTS FISCAL 2011 FIRST QUARTER FINANCIAL RESULTS ARROWHEAD REPORTS FISCAL 2011 FIRST QUARTER FINANCIAL RESULTS PASADENA, Calif. – February 10, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal	View HTML ARROWHEAD REPORTS FISCAL 2011 FIRST QUARTER FINANCIAL RESULTS 19.1 KB
Toggle Summary Feb 9, 2011	Arrowhead Research to Present at the 13th Annual BIO CEO & Investor Conference Arrowhead Research to Present at the 13th Annual BIO CEO & Investor Conference PASADENA, Calif. — February 9, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR ), a nanomedicine company, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the 13th Annual BIO	View HTML Arrowhead Research to Present at the 13th Annual BIO CEO & Investor Conference 12.3 KB
Toggle Summary Feb 6, 2011	Arrowhead Research to Report Fiscal 2011 First Quarter Financial Results and Host Conference Call on Thursday, February 10, 2011 Arrowhead Research to Report Fiscal 2011 First Quarter Financial Results and Host Conference Call on Thursday, February 10, 2011 PASADENA, Calif. — February 4, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a focused nanomedicine holding company, today announced that it will report its	View HTML Arrowhead Research to Report Fiscal 2011 First Quarter Financial Results and Host Conference Call on Thursday, February 10, 2011 12 KB
Toggle Summary Jan 18, 2011	Arrowhead Subsidiary Unidym, Inc. Acquired by Wisepower Co., Ltd. for up to $140 million earn-out plus $5 million upfront Arrowhead Subsidiary Unidym, Inc. Acquired by Wisepower Co., Ltd. for up to $140 million earn-out plus $5 million upfront PASADENA, Calif. - January 18, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Unidym, Inc. subsidiary has been acquired by Wisepower Co., Ltd., a	View HTML Arrowhead Subsidiary Unidym, Inc. Acquired by Wisepower Co., Ltd. for up to $140 million earn-out plus $5 million upfront 15.8 KB
Toggle Summary Jan 8, 2011	Arrowhead Increases Investment in RNAi Subsidiary Calando Pharmaceuticals Arrowhead Increases Investment in RNAi Subsidiary Calando Pharmaceuticals PASADENA, Calif. – January 18, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR) (“the Company”) today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted	View HTML Arrowhead Increases Investment in RNAi Subsidiary Calando Pharmaceuticals 13 KB